{"id":1666,"date":"2017-07-26T23:27:56","date_gmt":"2017-07-27T03:27:56","guid":{"rendered":"https:\/\/patents.harnessip.com\/?p=1666"},"modified":"2017-08-04T19:19:12","modified_gmt":"2017-08-04T23:19:12","slug":"reasonable-expectation-of-success-not-absolute-predictability-is-all-that-is-required-for-obviousness","status":"publish","type":"post","link":"https:\/\/patents.harnessip.com\/?p=1666","title":{"rendered":"Reasonable Expectation of Success, Not Absolute Predictability, is All that is Required for Obviousness"},"content":{"rendered":"<p>In\u00a0<a href=\"http:\/\/www.cafc.uscourts.gov\/sites\/default\/files\/opinions-orders\/16-1814.Opinion.7-24-2017.1.PDF\">Soft Gel Techs., Inc. v. Jarrow Formulas, Inc.<\/a>, [16-1814](July 26, 2017), the Federal Circuit affirmed the PTAB decision review <em>inter partes<\/em> reexamination, that claims in U.S. Patent Nos.\u00a08,124,072, 8,105,583, and 8,147,826, directed to CoQ10 in solvents known as monoterpenes, were invalid for obviousness.<\/p>\n<p>In trying to resurrect its claims, Soft Gel pointed to a later article reflecting follow up research, the necessity of which, it argued showed that earlier references did not make the claimed invention obvious. \u00a0The Federal Circuit called Soft Gel out, stating that \u00a0that it argued showed that Soft Gel was applying an incorrect\u00a0legal standard for obviousness, requiring \u201cabsolute\u00a0predictability\u201d rather than simply \u201ca reasonable expectation of<br \/>\nsuccess.\u201d \u00a0The Federal Circuit said:<\/p>\n<blockquote><p>A supplemental\u00a0study does not imply lack of awareness of the\u00a0likely result; rather, studies are frequently conducted to\u00a0confirm what is suspected to be true. An incentive to\u00a0conduct a confirmatory study frequently exists even when\u00a0one has every reason to expect success.<\/p><\/blockquote>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In\u00a0Soft Gel Techs., Inc. v. Jarrow Formulas, Inc., [16-1814](July 26, 2017), the Federal Circuit affirmed the PTAB decision review inter partes reexamination, that claims in U.S. Patent Nos.\u00a08,124,072, 8,105,583, and 8,147,826, directed to CoQ10 in solvents known as monoterpenes, were &hellip; <a href=\"https:\/\/patents.harnessip.com\/?p=1666\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[],"class_list":["post-1666","post","type-post","status-publish","format-standard","hentry","category-obviousness"],"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=\/wp\/v2\/posts\/1666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1666"}],"version-history":[{"count":1,"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=\/wp\/v2\/posts\/1666\/revisions"}],"predecessor-version":[{"id":1667,"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=\/wp\/v2\/posts\/1666\/revisions\/1667"}],"wp:attachment":[{"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/patents.harnessip.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}